Supplementary Figures 1-15 from Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling

Le résumé fourni par la source

S1. TP63 expression is downregulated in late-stage human larynx HNSCCs. S2. Histopathological analysis of mouse tongue SCCs. S3. TP63 and KRT14 (epithelial marker) expression is lost in a subset of human HNSCC cell lines. S4. Loss of TP63 in HNSCC cell lines does not alter cell cycle distribution. S5. Loss of TP63 promotes the migration and invasion of HNSCC cell lines. S6. Loss of TP63 promotes cervical lymph node metastasis in vivo. S7. Loss of TP63 promotes cervical lymph node metastasis of CAL27 cells. S8. Loss of TP63 in HNSCCs does not alter E-cadherin localization. S9. TP63 regulated pathways in HNSCCs identified using Gene Set Enrichment analysis (GSEA). S10. Loss of TP63 in HNSCCs does not alter P-STAT3 (Tyr705) expression. S11. MAPK and P-STA3 (Ser 727) signaling is upregulated in poorly-differentiated larynx SCCs. S12. EGF treatment of HNSCC cells leads to upregulation of P-ERK1/2, P-STAT3 (Ser 727), and MMP-15 in HNSCC cells. S13. Inhibition of MAPK signaling in HNSCC cell lines by treatment with Trametinib. S14. Inhibition of MAPK signaling by Trametinib prevents the cervical lymph node metastasis of TP63 knockdown HNSCCs. S15. Inhibition of MAPK signaling by Trametinib treatment prevents the cervical lymph node metastasis of CAL27-TP63 shRNA3 HNSCCs.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.